Current
AI-Care project funded with 5 million euros
The diagnosis of glioblastoma is associated with a poor chance of survival. The brain tumor is among the most aggressive types of cancer. Medications are not very effective, partly because individual tumor cells develop resistance to them. The reason for this is the subject of a new research project, which is being funded by the Carl Zeiss Foundation for six years with five million euros. Using artificial intelligence (AI), the project participants aim to decipher these mechanisms to prevent the tumor from becoming resistant and to enable individualized therapies. The project is coordinated at the Rhineland-Palatinate Technical University Kaiserslautern-Landau (RPTU) by Professor Naim Bajcinca and Dr. Sandesh Hiremath. In addition, working groups from biology, computer science, and mathematics (Professor Dr. Anna Hundertmark, Professor Dr. Nicolas R. Gauger) are involved at RPTU. Furthermore, bioinformaticians from the University of Heidelberg as well as life scientists from the German Cancer Research Center in Heidelberg are participating in the project. It is funded by the Carl Zeiss Foundation as part of the funding program 'CZS Breakthroughs,' which in 2023 was announced under 'AI in Health.'